Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: osteoporosis

Osteoporosis Drugs Don’t Reduce Overall Mortality

Megan Brooks  |  August 21, 2019

NEW YORK (Reuters Health)—Anti-fracture medications do not reduce overall mortality in older patients with osteoporosis, according to an updated systematic review and meta-analysis. “This meta-analysis suggests drug treatments, including treatment with bisphosphonates, for osteoporosis should be recommended only for the prevention of fracture and not for any additional reduction in mortality,” researchers write in JAMA…

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:FracturesmortalityOsteoporosisosteoporosis treatments

U.S. Supreme Court Tosses Ruling Against Merck on Fosamax Osteoporosis Drug

Andrew Chung  |  May 22, 2019

WASHINGTON (Reuters)—On May 20, the U.S. Supreme Court threw out a lower court ruling that had revived hundreds of lawsuits accusing Merck & Co. of failing to properly warn patients of debilitating thigh-bone fractures as a result of taking its osteoporosis drug alendronic acid (Fosamax). The nine justices unanimously directed the Philadelphia-based 3rd U.S. Circuit…

Filed under:ConditionsDrug UpdatesLegal UpdatesOsteoarthritis and Bone Disorders Tagged with:alendronic acidFosamaxfracture riskFracturesMerck & CoOsteoporosisosteoporosis treatmentsU.S. Supreme Court

FDA Approves New Osteoporosis Medication

Michele B. Kaufman, PharmD, BCGP  |  April 23, 2019

Romosozumab-aqqg has been approved in the U.S. for treating postmenopausal women with osteoporosis at high risk of fracture…

Filed under:ConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:FDAOsteoporosisosteoporosis treatmentspostmenopausalpostmenopausal womenromosozumab-aqqgU.S. Food and Drug Administration (FDA)

FDA Greenlights Osteoporosis Drug for Postmenopausal Women

Saumya Joseph  |  April 11, 2019

(Reuters)—The U.S. Food and Drug Administration says it has approved Amgen’s osteoporosis treatment for postmenopausal women who are at high risk of fracture. Evenity (romosozumab-aqqg), developed jointly with Belgium-based UCB SA, helps reduce the risk of fracture by increasing bone mass and mildly inhibiting the break down of bone minerals. Romosozumab-aqqg belongs to a new…

Filed under:ConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:AmgenFDAFDA approvalFracturesOsteoporosisosteoporosis treatmentspostmenopausalpostmenopausal womenromosozumabromosozumab-aqqgU.S. Food and Drug Administration (FDA)

Osteoporosis Experts Discuss Bisphosphonates, Chronic Kidney Disease

Lara C. Pullen, PhD  |  March 19, 2019

CHICAGO—The osteoporosis session at the 2018 ACR/ARHP Annual Meeting opened with a discussion by Kenneth Saag, MD, MSc, professor of medicine at the University of Alabama, Birmingham, in which he highlighted adverse events associated with osteoporosis medications. Dr. Saag began his presentation by emphasizing that, above all, the audience should keep in mind that the…

Filed under:ConditionsMeeting ReportsOsteoarthritis and Bone Disorders Tagged with:2018 ACR/ARHP Annual MeetingAssociation of Rheumatology Professionals (ARP)bisphosphonateschronic kidney diseaseOsteoporosis

Do Osteoporosis Screening Guidelines Meet Patient Needs?

Lara C. Pullen, PhD  |  January 21, 2019

A recent study found that clinical practice guidelines for osteoporosis screening vary in quality and recommendations—even within the same country. Assessing guidelines from 13 countries, researchers found osteoporosis screening standards have not improved over time and many fail to include patients in guideline development…

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:GuidelinesOsteoporosisscreening

A Balancing Act: Tips to Ensure Optimal Screening & Treatment for Osteoporosis

Carina Stanton  |  November 12, 2018

Patients with rheumatic diseases may be undertreated for osteoporosis. To decrease fracture risk for at-risk patients, rheumatologists can engage patients in shared decision making with regular screening and education about treatment options…

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:bonefracture riskFracturesOsteoporosispatient care

Antibodies Against Oxidized Phospholipids Protect Against Osteoporosis

Mary Beth Nierengarten  |  October 18, 2018

It has long been known that hyperlipidemia adversely affects bone, but the exact pathologic mechanism(s) underlying hyperlipidemia-induced bone loss has not been fully understood. Until now. Pathogenesis of Osteoporosis New research by Ambrogini and colleagues shows that oxidation-specific epitopes derived from lipid peroxidation contribute to the pathogenesis of osteoporosis.1 Importantly, the research shows that innate…

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:atherosclerosisbone lossOsteoporosis

Osteoporosis Drugs Tied to Lower Fracture Risk & Health Costs

Lisa Rapaport  |  August 13, 2018

(Reuters Health)—Older women with osteoporosis who consistently take a bisphosphonate may have a lower risk of fractures and lower total health costs than their counterparts who stop taking these drugs, a U.S. study suggests. Researchers examined data on 294,369 women who were at least 66 years old, insured by Medicare and prescribed osteoporosis medicines for…

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:bisphosphonatesfracture riskFracturesOsteoporosisosteoporosis treatments

Improve Your Recognition & Treatment of Osteoporosis

Jason Liebowitz, MD, FACR  |  July 19, 2018

BALTIMORE—Rheumatologists may not think about osteoporosis on a daily basis, but they should, said Dr. Karl Insogna, the Ensign Professor of Medicine at Yale University School of Medicine and director of the Yale Bone Center in New Haven, Conn., in his recent lecture at the Maryland Society for the Rheumatic Diseases. With approximately 75 million…

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:alendronatebisphosphonatesCorticosteroidsdenosumabOsteoporosisraloxifenerisedronateteriparatidezoledronic acid

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 58
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences